ASTRAZENECA PLC (ZEG.DE) Stock Fundamental Analysis
Europe - FRA:ZEG - GB0009895292 - Common Stock
146.5 EUR
+0.7 (+0.48%)
ZEG gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 54 industry peers in the Pharmaceuticals industry. While ZEG belongs to the best of the industry regarding profitability, there are concerns on its financial health. While showing a medium growth rate, ZEG is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year ZEG was profitable.
In the past year ZEG had a positive cash flow from operations.
Each year in the past 5 years ZEG has been profitable.
In the past 5 years ZEG always reported a positive cash flow from operatings.
1.2 Ratios
ZEG's Return On Assets of 8.21% is fine compared to the rest of the industry. ZEG outperforms 64.81% of its industry peers.
With a decent Return On Equity value of 20.48%, ZEG is doing good in the industry, outperforming 66.67% of the companies in the same industry.
With a decent Return On Invested Capital value of 14.42%, ZEG is doing good in the industry, outperforming 70.37% of the companies in the same industry.
ZEG had an Average Return On Invested Capital over the past 3 years of 11.62%. This is below the industry average of 14.87%.
The last Return On Invested Capital (14.42%) for ZEG is above the 3 year average (11.62%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROIC | 14.42% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
1.3 Margins
ZEG's Profit Margin of 16.17% is fine compared to the rest of the industry. ZEG outperforms 66.67% of its industry peers.
In the last couple of years the Profit Margin of ZEG has grown nicely.
ZEG's Operating Margin of 24.34% is fine compared to the rest of the industry. ZEG outperforms 61.11% of its industry peers.
ZEG's Operating Margin has improved in the last couple of years.
The Gross Margin of ZEG (81.90%) is better than 83.33% of its industry peers.
In the last couple of years the Gross Margin of ZEG has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% |
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ZEG is still creating some value.
Compared to 1 year ago, ZEG has about the same amount of shares outstanding.
Compared to 5 years ago, ZEG has more shares outstanding
ZEG has a worse debt/assets ratio than last year.
2.2 Solvency
ZEG has an Altman-Z score of 5.59. This indicates that ZEG is financially healthy and has little risk of bankruptcy at the moment.
ZEG has a Altman-Z score of 5.59. This is in the better half of the industry: ZEG outperforms 75.93% of its industry peers.
The Debt to FCF ratio of ZEG is 3.41, which is a good value as it means it would take ZEG, 3.41 years of fcf income to pay off all of its debts.
ZEG's Debt to FCF ratio of 3.41 is in line compared to the rest of the industry. ZEG outperforms 57.41% of its industry peers.
ZEG has a Debt/Equity ratio of 0.61. This is a neutral value indicating ZEG is somewhat dependend on debt financing.
The Debt to Equity ratio of ZEG (0.61) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Altman-Z | 5.59 |
ROIC/WACC1.6
WACC8.99%
2.3 Liquidity
ZEG has a Current Ratio of 0.88. This is a bad value and indicates that ZEG is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.88, ZEG is not doing good in the industry: 81.48% of the companies in the same industry are doing better.
ZEG has a Quick Ratio of 0.88. This is a bad value and indicates that ZEG is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of ZEG (0.69) is worse than 77.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 |
3. Growth
3.1 Past
ZEG shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.89%.
The Earnings Per Share has been growing by 18.59% on average over the past years. This is quite good.
The Revenue has grown by 13.52% in the past year. This is quite good.
The Revenue has been growing by 17.27% on average over the past years. This is quite good.
EPS 1Y (TTM)4.89%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%-42.79%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
3.2 Future
The Earnings Per Share is expected to grow by 12.73% on average over the next years. This is quite good.
Based on estimates for the next years, ZEG will show a small growth in Revenue. The Revenue will grow by 7.18% on average per year.
EPS Next Y13.8%
EPS Next 2Y13.64%
EPS Next 3Y12.91%
EPS Next 5Y12.73%
Revenue Next Year9.58%
Revenue Next 2Y7.79%
Revenue Next 3Y7.12%
Revenue Next 5Y7.18%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 21.32 indicates a rather expensive valuation of ZEG.
Compared to the rest of the industry, the Price/Earnings ratio of ZEG is on the same level as its industry peers.
ZEG's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.06.
With a Price/Forward Earnings ratio of 15.97, ZEG is valued correctly.
The rest of the industry has a similar Price/Forward Earnings ratio as ZEG.
ZEG's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 32.73.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.32 | ||
| Fwd PE | 15.97 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ZEG indicates a slightly more expensive valuation: ZEG is more expensive than 62.96% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, ZEG is valued a bit more expensive than the industry average as 61.11% of the companies are valued more cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 54.89 | ||
| EV/EBITDA | 26.45 |
4.3 Compensation for Growth
ZEG's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of ZEG may justify a higher PE ratio.
ZEG's earnings are expected to grow with 12.91% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.55
PEG (5Y)1.15
EPS Next 2Y13.64%
EPS Next 3Y12.91%
5. Dividend
5.1 Amount
ZEG has a Yearly Dividend Yield of 1.91%.
Compared to an average industry Dividend Yield of 2.89, ZEG has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 2.36, ZEG has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.91% |
5.2 History
The dividend of ZEG has a limited annual growth rate of 1.40%.
Dividend Growth(5Y)1.4%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
ZEG pays out 52.89% of its income as dividend. This is a bit on the high side, but may be sustainable.
ZEG's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP52.89%
EPS Next 2Y13.64%
EPS Next 3Y12.91%
FRA:ZEG (11/7/2025, 7:00:00 PM)
146.5
+0.7 (+0.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners48.98%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap454.23B
Revenue(TTM)58.13B
Net Income(TTM)9.40B
Analysts82.42
Price Target156.83 (7.05%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.91% |
Yearly Dividend2.58
Dividend Growth(5Y)1.4%
DP52.89%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-25.51%
Min EPS beat(2)-49.27%
Max EPS beat(2)-1.74%
EPS beat(4)1
Avg EPS beat(4)-10.58%
Min EPS beat(4)-49.27%
Max EPS beat(4)9.32%
EPS beat(8)3
Avg EPS beat(8)-5.46%
EPS beat(12)7
Avg EPS beat(12)-1.7%
EPS beat(16)11
Avg EPS beat(16)0.58%
Revenue beat(2)0
Avg Revenue beat(2)-0.23%
Min Revenue beat(2)-0.24%
Max Revenue beat(2)-0.22%
Revenue beat(4)1
Avg Revenue beat(4)-0.43%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)2.7%
Revenue beat(8)3
Avg Revenue beat(8)0.08%
Revenue beat(12)4
Avg Revenue beat(12)-0.52%
Revenue beat(16)6
Avg Revenue beat(16)0.18%
PT rev (1m)1.26%
PT rev (3m)0.3%
EPS NQ rev (1m)-0.35%
EPS NQ rev (3m)-0.66%
EPS NY rev (1m)0.05%
EPS NY rev (3m)1.17%
Revenue NQ rev (1m)0.19%
Revenue NQ rev (3m)0.2%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)0.89%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.32 | ||
| Fwd PE | 15.97 | ||
| P/S | 9.03 | ||
| P/FCF | 54.89 | ||
| P/OCF | 34.69 | ||
| P/B | 11.44 | ||
| P/tB | N/A | ||
| EV/EBITDA | 26.45 |
EPS(TTM)6.87
EY4.69%
EPS(NY)9.17
Fwd EY6.26%
FCF(TTM)2.67
FCFY1.82%
OCF(TTM)4.22
OCFY2.88%
SpS16.22
BVpS12.8
TBVpS-3.77
PEG (NY)1.55
PEG (5Y)1.15
Graham Number44.48
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROCE | 17.6% | ||
| ROIC | 14.42% | ||
| ROICexc | 16.02% | ||
| ROICexgc | 81.56% | ||
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% | ||
| FCFM | 16.46% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ROICexc(3y)12.66%
ROICexc(5y)10.55%
ROICexgc(3y)112.76%
ROICexgc(5y)85.06%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexgc growth 3Y43.28%
ROICexgc growth 5Y4.77%
ROICexc growth 3Y41%
ROICexc growth 5Y11.99%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Debt/EBITDA | 1.34 | ||
| Cap/Depr | 84.97% | ||
| Cap/Sales | 9.59% | ||
| Interest Coverage | 10.83 | ||
| Cash Conversion | 73.11% | ||
| Profit Quality | 101.79% | ||
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 | ||
| Altman-Z | 5.59 |
F-Score7
WACC8.99%
ROIC/WACC1.6
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)4.89%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%-42.79%
EPS Next Y13.8%
EPS Next 2Y13.64%
EPS Next 3Y12.91%
EPS Next 5Y12.73%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
Revenue Next Year9.58%
Revenue Next 2Y7.79%
Revenue Next 3Y7.12%
Revenue Next 5Y7.18%
EBIT growth 1Y26.07%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year34.36%
EBIT Next 3Y17.49%
EBIT Next 5Y13.09%
FCF growth 1Y37.12%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y46.1%
OCF growth 3Y25.76%
OCF growth 5Y31.92%
ASTRAZENECA PLC / ZEG.DE FAQ
What is the fundamental rating for ZEG stock?
ChartMill assigns a fundamental rating of 5 / 10 to ZEG.DE.
What is the valuation status for ZEG stock?
ChartMill assigns a valuation rating of 3 / 10 to ASTRAZENECA PLC (ZEG.DE). This can be considered as Overvalued.
What is the profitability of ZEG stock?
ASTRAZENECA PLC (ZEG.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for ZEG stock?
The Price/Earnings (PE) ratio for ASTRAZENECA PLC (ZEG.DE) is 21.32 and the Price/Book (PB) ratio is 11.44.
Can you provide the financial health for ZEG stock?
The financial health rating of ASTRAZENECA PLC (ZEG.DE) is 3 / 10.